Ann: Q4 FY24 Quarterly Activities Report and Appendix 4C, page-11

Amazing that the 20-40 million contract and the Hume contract have added little uplift to the current share price. Does anyone know how many more of these opportunities still exist in the UK? Where else is the new revenue going to come from? The cash position is great, but based on what I am seeing, it will be a long time (3-4 years?) before decent profit is possible for dividends or returns from this company, or even to recoup the Silverlink investment.

I watched the webinar; Kate has written off the primary care market and PAS being used in Australia. At one point she said there are low margins in primary care space. What is better low margin or no revenue?? I think the CEO's time is up if she is unable to generate value or handle large CRs appropriately. There is no point in having great tech if they don't know how to sell it.